Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma
- PMID: 26851021
Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma
Abstract
Background: Secreted frizzled-related protein-1 (SFRP1) is a well-known inhibitor of the wingless type (WNT)-β-catenin signaling pathway and its inactivation plays an important role in the development and progression of various types of cancer. However, the clinical significance of SFRP1 expression in patients with hepatocellular carcinoma (HCC) remains unknown.
Materials and methods: A total of 63 patients with HCC who underwent hepatectomy at our Institution were enrolled in this study. A quantitative real-time polymerase chain reaction (RT-PCR) was performed to determine the SFRP1 mRNA expression level in both the tumorous and non-tumorous tissues of HCC. The patients were divided into low and high gene-expression groups based on the SFRP1 gene expression level in their tumor tissues. We analyzed the differences in clinicopathological characteristics between these two groups of patients.
Result: The expression level of SFRP1 was significantly lower in tumor tissue than in non-tumor tissue (p<0.0001). Significant correlations were observed between a high expression of SFRP1 in tumor tissue and older than 65 years (p=0.030), tumor size less than 5 cm (p=0.011); and no vascular invasion (p=0.004). Patients with high SFRP1 expression in tumor tissue had a significantly better overall survival rate (p=0.040). However, the SFRP1 expression level was not defined as an independent risk factor for patient survival based on results of multivariate analysis.
Conclusion: SFRP1 may play a role in the development and progression of HCC. Therefore, more studies are required to investigate a potential role of SFRP1 in HCC prognosis.
Keywords: Hepatocellular carcinoma; SFRP1; prognostic factor.
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells.Neoplasma. 2012;59(3):326-32. doi: 10.4149/neo_2012_042. Neoplasma. 2012. PMID: 22296502
-
Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649. World J Gastroenterol. 2015. PMID: 26074703 Free PMC article.
-
High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.Anticancer Res. 2016 Feb;36(2):757-62. Anticancer Res. 2016. PMID: 26851035
-
A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.Drug Des Devel Ther. 2015 Jul 15;9:3625-33. doi: 10.2147/DDDT.S86032. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26203228 Free PMC article. Review.
-
CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma.Cancer Genomics Proteomics. 2017 Nov-Dec;14(6):445-453. doi: 10.21873/cgp.20054. Cancer Genomics Proteomics. 2017. PMID: 29109094 Free PMC article. Review.
Cited by
-
SFRP1 in Skin Tumor Initiation and Cancer Stem Cell Regulation with Potential Implications in Epithelial Cancers.Stem Cell Reports. 2020 Feb 11;14(2):271-284. doi: 10.1016/j.stemcr.2019.12.006. Epub 2020 Jan 9. Stem Cell Reports. 2020. PMID: 31928951 Free PMC article.
-
Obesity-associated miR-27a upregulation promotes hepatocellular carcinoma metastasis through suppressing SFRP1.Onco Targets Ther. 2018 Jun 1;11:3281-3292. doi: 10.2147/OTT.S162978. eCollection 2018. Onco Targets Ther. 2018. PMID: 29910623 Free PMC article.
-
Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.J Gastrointest Surg. 2021 Jan;25(1):112-124. doi: 10.1007/s11605-020-04554-1. Epub 2020 Mar 3. J Gastrointest Surg. 2021. PMID: 32128678
-
Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma.Oncotarget. 2020 Dec 29;11(52):4803-4812. doi: 10.18632/oncotarget.27852. eCollection 2020 Dec 29. Oncotarget. 2020. PMID: 33447348 Free PMC article.
-
Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis.Oncotarget. 2022 Nov 22;13:1286-1298. doi: 10.18632/oncotarget.28306. Oncotarget. 2022. PMID: 36441784 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials